TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01413906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-833923 (XL139)
Description: Capsule, Oral, 150 mg, 300 mg, or 450 mg,Once daily, Until progression of disease, unacceptable toxicity, withdrawal of subject's consent or meeting other discontinuation criteria
Study: NCT02543177

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: coronary angiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: coronary angiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: coronary angiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: coronary angiography

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ischemic precondition
Description: four cycles of congestion and flow of blood in the arm of the patient for 5 minutes
Study: NCT01905800

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biaxial rotational chair
Description: This chair has a vertical and a horizontal axis of rotation and is lockable in preset positions. It is manually handled and can swivel between two axes in all planes of the semicircular canals for up to 360 degrees or more. Velocity of rotation can be regulated freely.
Study: NCT02543177

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ischemic precondition
Description: four cycles of congestion and flow of blood in the arm of the patient for 5 minutes

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prior kidney irrigation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: prior kidney irrigation
Study: NCT02126553

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide
Description: Given PO
Study: NCT02086487

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg.
Description: Patients diagnosed with chronic myeloid leukemia receiving treatment of Imatinib 400 mg once a day but are determined to be sub-optimally responding to Imatinib therapy as per the ELN 2013 guidelines will be switched to Nilotinib 300 mg BID and then will be assessed for therapy response. ELN guidelines 2013 for imatinib therapy response states as:~Minor cytogenetic response mCyR or minimal response at 3 months (Ph+ metaphases in BM 35 to 95 %); BCR-ABL1 transcript \> 10% at 3 months; Partial cytogenetic response at 6 months Ph+ metaphases in BM 0to 35); BCR-ABL1 transcript is 1 to 10% at 6 months. Less than a major molecular response at \> 12 months; i.e (BCR-ABL1 0.1 -1%)
Study: NCT03070171

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: single dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dabigatran etexilate
Description: single dose
Study: NCT02161094

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Give incentives to physicians based on their patient's HbA1c improvement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Give incentives to physicians based on their patient's HbA1c improvement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Give incentives to patients based on their own HbA1c improvement

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Give incentives to patients based on their own HbA1c improvement
Study: NCT04286490

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Prone position
Description: Abdomen suspension in prone position
Study: NCT03587116

Intervention type: DRUG
Group type: OTHER
Intervention: Standard of Care FIX Replacement therapy
Description: There is no investigational product being administered. Subjects will be administering their own standard of care FIX replacement therapy.

Intervention type: DRUG
Group type: OTHER
Intervention: Standard of Care FVIII Replacement therapy
Description: There is no investigational product being administered. Subjects will be administering their own standard of care FVIII replacement therapy.
Study: NCT02362503

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BMS-663068
Description: BMS-663068

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-663068
Description: BMS-663068

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT03709264

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amino Acids
Description: Patients randomized to experimental arm receive a continuous infusion of a balanced mixture of amino acids in a dose of 2 g/kg ideal body weight/day (to a maximum 100 g/day) from the operating room admission up to either death, start of RRT, ICU discharge or 72 hours after treatment initiation, trough a central venous line

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebos
Description: Placebo: standard treatment
Study: NCT01905800

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Biaxial rotational chair
Description: This chair has a vertical and a horizontal axis of rotation and is lockable in preset positions. It is manually handled and can swivel between two axes in all planes of the semicircular canals for up to 360 degrees or more. Velocity of rotation can be regulated freely.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Biaxial rotational chair
Description: This chair has a vertical and a horizontal axis of rotation and is lockable in preset positions. It is manually handled and can swivel between two axes in all planes of the semicircular canals for up to 360 degrees or more. Velocity of rotation can be regulated freely.
Study: NCT03477305

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Blackberry Consumption
Description: Measures of biomedical and behavioral changes resulting from the consumption of blackberries.
Study: NCT03500523

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: corneal biomechanical properties
Description: We want to investigate changes of corneal biomechanical properties during pregnancy. The Ocular Response Analyzer (ORA) evaluate the in vivo corneal biomechanical properties in form of corneal hysteresis (CH) and corneal resistance factor (CRF)
Study: NCT03360838

Intervention type: OTHER
Intervention: CogCheck
Description: Performance of study participants in the application
Study: NCT01874353

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olaparib 300mg tablets
Description: 300mg Olaparib or placebo tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to match olaparib 300mg
Description: 300mg Olaparib or placebo tablets taken orally twice daily until objective radiological disease progression as per RECIST as assessed by the investigator (or as long as in the investigator's opinion they are benefiting from treatment and they do not meet any other discontinuation criteria). Dose reduction to 250mg and subsequently 200mg is permitted following confirmation of toxicity.
Study: NCT01663454

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cogmed Robomemo working memory training
Description: The Cogmed Robomemo program is designed as a computer game in which an animated robot gives different tasks to be solved by the child. The tasks have various degrees of difficulty adapted continuously throughout the intervention period to the performance of the individual child. The program is standardized in that each child receives the same set of tasks during the training period. The child will perform the training sessions at home using their own computer for about 35-40 minutes each day.
Study: NCT01712620

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Spironolactone
Description: Initial dose, 25 mg (pink capsule) orally, daily. If well tolerated at 7-9 wks then increased to 50 mg (brown capsule) daily.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Initial dose, pink sugar capsule, daily. If well tolerated at 7-9 wks then changed to brown sugar capsule, daily.
Study: NCT01758549

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Aggressive Intravenous Hydration Group
Description: Patients in the intravenous hydration group wll be treated with lactated ringer infusion at a rate of 3cc/kg/hour during the procedure, be given a bolus of 20cc/kg immediately afterward and receive an infusion of 3cc/kg/hour for 8 hours after the procedure.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard Fluids Arm
Description: Patients randomized to the standard fluids arm will receive lactated ringers at an infusion rate of 1.5cc/kg/hour during the procedure, will receive no bolus, and will receive an infusion of lactated ringers at 1.5cc/kg for 8 hours after the procedure.
Study: NCT03616015

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: blood samples
Description: 20 to 30 ml of blood sample (D0, D15, D30, D60, D90, D180, Y1, Y2)

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: fecal samples
Description: 1 g of feces (D-8, D0, D15, D30, D90)

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Anxiety test
Description: Test of Spielberger

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress test
Description: Test of Cohen
Study: NCT03677037

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Short-term MBT
Description: Short-term mentalization-based therapy

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Long-term MBT
Description: Long-term mentalization-based therapy
Study: NCT01473485

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ExAblate Transcranial System
Description: MR Guided Focused Ultrasound
Study: NCT02169869

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Mirena
Description: A radio-opaque T-shaped polyethylene device containing 52mg of levonorgestrel dispersed in polydimethylsiloxane on its stem. The progestin is released at a rate of 15 mcg per day.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mirena
Description: A radio-opaque T-shaped polyethylene device containing 52mg of levonorgestrel dispersed in polydimethylsiloxane on its stem. The progestin is released at a rate of 15 mcg per day.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Paragard
Description: A T-shaped polyethylene device with 380 mm2 of exposed surface area of fine copper wire wound around its arms and stem. Barium sulfate has been added to the polyethylene frame to make the device radio-opaque. A 3-mm plastic ball is located at the base of the IUD, through which the polyethylene monofilament string passes.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Paragard
Description: A T-shaped polyethylene device with 380 mm2 of exposed surface area of fine copper wire wound around its arms and stem. Barium sulfate has been added to the polyethylene frame to make the device radio-opaque. A 3-mm plastic ball is located at the base of the IUD, through which the polyethylene monofilament string passes.
Study: NCT03792932

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laparoscopic distal pancreatectomy
Description: Laparoscopic distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Open distal pancreatectomy
Description: Open distal pancreatectomy includes distal pancreatectomy, splenectomy, and regional lymph nodes resection for pancreatic cancer at the body and tail. Regional lymph nodes includes group 8, 10, 11, 18, 7, 9, 14, 15, according to the 2003 edition of lymph nodes group system defined by Japan Pancreas Society (JPS).
Study: NCT00879710

Intervention type: DRUG
Group type: OTHER
Intervention: simvastatin or ezetimibe
Description: Subjects will be started on either simvastatin or ezetimibe (we will alternate the subjects so that half the sample will initially be treated with simvastatin and half will be started on ezetimibe). The dose of Simvastatin (Merck) is 40 mg orally at nighttime for 6 weeks and the dose of ezetimibe (Schering-Plough) is 10 mg taken orally once a day. Subjects will be instructed on low-fat diet (therapeutic life style changes diet) recommended by American Heart Association by the bionutritionist.

Intervention type: DRUG
Group type: OTHER
Intervention: simvastatin or ezetimibe
Description: Subjects will be started on either simvastatin or ezetimibe (we will alternate the subjects so that half the sample will initially be treated with simvastatin and half will be started on ezetimibe). The dose of Simvastatin (Merck) is 40 mg orally at nighttime for 6 weeks and the dose of ezetimibe (Schering-Plough) is 10 mg taken orally once a day. Subjects will be instructed on low-fat diet (therapeutic life style changes diet) recommended by American Heart Association by the bionutritionist.

Intervention type: DRUG
Group type: OTHER
Intervention: simvastatin or ezetimibe
Description: Subjects will be started on either simvastatin or ezetimibe (we will alternate the subjects so that half the sample will initially be treated with simvastatin and half will be started on ezetimibe). The dose of Simvastatin (Merck) is 40 mg orally at nighttime for 6 weeks and the dose of ezetimibe (Schering-Plough) is 10 mg taken orally once a day. Subjects will be instructed on low-fat diet (therapeutic life style changes diet) recommended by American Heart Association by the bionutritionist.

Intervention type: DRUG
Group type: OTHER
Intervention: simvastatin or ezetimibe
Description: Subjects will be started on either simvastatin or ezetimibe (we will alternate the subjects so that half the sample will initially be treated with simvastatin and half will be started on ezetimibe). The dose of Simvastatin (Merck) is 40 mg orally at nighttime for 6 weeks and the dose of ezetimibe (Schering-Plough) is 10 mg taken orally once a day. Subjects will be instructed on low-fat diet (therapeutic life style changes diet) recommended by American Heart Association by the bionutritionist.
Study: NCT02131584

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire Administration
Description: Ancillary studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib Phosphate
Description: Given PO
Study: NCT03575936

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Home INR Monitoring
Description: The self-monitoring group will monitor INR at home using the AlereTM Home Monitoring Service. They will call in the weekly results to Alere or submit online via the patient portal, which is the standard protocol among home monitoring patients. Alere will then upload the information to a password-protected HIPAA compliant website that only study investigators will be able to access. Pharmacists will have real-time access to the test results via the web interface. Pharmacists can follow up in real time if the patient forgets to self-test. An alert will also be sent to the pharmacists via email to follow up on any out of range results. This will help streamline pharmacists' workload to dedicate face-to-face time for patients that require such intervention. All home monitoring patients will be seen in clinic by the pharmacist at the end of the 3-month randomization period in order to assess compliance with meter-use and re-evaluate meter-use competency.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: The patients in the standard of care group will have a clinic visit with the pharmacist at least once every 4 weeks or earlier, as deemed necessary by the pharmacist. The duration of the randomization period will be three months. At the end of the 3-month randomization period, patients will be provided the opportunity to cross over from the home INR monitoring group to the pharmacist-managed clinic group, or vice versa. The remainder of the study duration (post-3 month analysis) will purely be for observational purposes, in order to account for the loss of randomization and potential bias. The total duration of the study will be one year.
Study: NCT01854151

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New Labeling/Dosing Strategy
Description: Parents whose children are prescribed liquid medication will receive medications with health literacy informed labels and dosing instruments
Study: NCT06143501

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Sample
Description: 6 ml blood (collection occurs once pre-transplantation and at three designated follow-up time points post-transplantation)

Intervention type: DIAGNOSTIC_TEST
Intervention: Blood Sample
Description: 6 ml blood (collection occurs once pre-transplantation and at three designated follow-up time points post-transplantation)

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool Sample
Description: pea-sized amount (collection occurs once pre-transplantation and at three designated follow-up time points post-transplantation)

Intervention type: DIAGNOSTIC_TEST
Intervention: Stool Sample
Description: pea-sized amount (collection occurs once pre-transplantation and at three designated follow-up time points post-transplantation)

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine Sample
Description: 8 ml (collection occurs once pre-transplantation and at three designated follow-up time points post-transplantation)

Intervention type: DIAGNOSTIC_TEST
Intervention: Urine Sample
Description: 8 ml (collection occurs once pre-transplantation and at three designated follow-up time points post-transplantation)
Study: NCT01053793

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glycemic response to different varieties of potatoes
Description: the glycemic response top 50g available carbohydrates from 4 potato varieties will be compared to a 50g glucose standard

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Glycemic response to different varieties of potatoes
Description: the glycemic response top 50g available carbohydrates from 4 potato varieties will be compared to a 50g glucose standard
Study: NCT04124432

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis will be smoked

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis will be smoked

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis will be smoked

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis will be smoked

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis will be smoked

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis will be smoked

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cannabis
Description: Cannabis will be smoked

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotine will be smoked or vaporized

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotine will be smoked or vaporized

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotine will be smoked or vaporized

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotine will be smoked or vaporized

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotine will be smoked or vaporized

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nicotine
Description: Nicotine will be smoked or vaporized
Study: NCT01970553

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lurbinectedin (PM01183)
Description: lurbinectedin (PM01183) is presented as powder for concentrate for solution for infusion with two strengths, 1-mg and 4-mg vials

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1000 mg vial, powder for injectable solution
Study: NCT01964781

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Topical administration - does it reduce surgical bleeding?

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: Topical administration - does it reduce surgical bleeding?

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bupivacaine
Description: Topical Bupivacaine- does it reduce surgical pain?

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adrenaline
Description: Topical adrenaline - does it reduce bleeding on its own, and does it enhance the effect of tranexamic acid?
Study: NCT02791932

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: See description above.
Study: NCT01028768

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Teduglutide
Description: 10 mg, one-time subcutaneous
Study: NCT03597581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ompenaclid
Description: RGX-202-01 (ompenaclid) is a small molecule inhibitor of the creatine transporter, SLC6a8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ompenaclid
Description: RGX-202-01 (ompenaclid) is a small molecule inhibitor of the creatine transporter, SLC6a8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ompenaclid
Description: RGX-202-01 (ompenaclid) is a small molecule inhibitor of the creatine transporter, SLC6a8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ompenaclid
Description: RGX-202-01 (ompenaclid) is a small molecule inhibitor of the creatine transporter, SLC6a8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ompenaclid
Description: RGX-202-01 (ompenaclid) is a small molecule inhibitor of the creatine transporter, SLC6a8.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: FOLFIRI is a chemotherapy regimen consisting of irinotecan, leucovorin, and 5-fluorouracil. Irinotecan is a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FOLFIRI
Description: FOLFIRI is a chemotherapy regimen consisting of irinotecan, leucovorin, and 5-fluorouracil. Irinotecan is a topoisomerase inhibitor, which prevents DNA from uncoiling and duplicating.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab is a vascular endothelial growth factor inhibitor.
Study: NCT01152619

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4989991
Description: Subcutaneous repeated dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RO4989991
Description: Subcutaneous repeated dose